Radiochemotherapy in stage III NSCLC Source: Annual Congress 2010 - PG23 Postgraduate Course: Case and problem-based multimodal treatment in thoracic oncology Year: 2010
Intraoperative photodinamic therapy as a part of combined radical treatment for stage III NSCLC Source: Annual Congress 2011 - Treatment of lung cancer Year: 2011
Indication and results of surgery in stage III NSCLC Source: Annual Congress 2010 - PG23 Postgraduate Course: Case and problem-based multimodal treatment in thoracic oncology Year: 2010
Postoperative adjuvant treatment in stage III NSCLC Source: Eur Respir J 2007; 30: Suppl. 51, 434s Year: 2007
Stage IIIA/B NSCLC: long-term results of induction chemotherapy and surgery Source: ISSN=ISSN 1810-6838, ISBN=, page=279 Year: 2008
Role of adjuvant/neoadjuvant treatment in stage I NSCLC Source: International Congress 2014 – Current therapeutic options in stage I non-small cell lung cancer (NSCLC) Year: 2014
Carboplatin-paclitaxel alone or with bevacizumab in stage III-IV lung adenocarcinoma Source: Annual Congress 2011 - Treatment of lung cancer Year: 2011
Pattern of response and recurrence after induction chemotherapy and [dsquote]involved field[dsquote] thoracic radiotherapy to 70 Gy in stage III NSCLC Source: Eur Respir J 2001; 18: Suppl. 33, 375s Year: 2001
Stage IIIA-N2 non-small cell lung cancer (NSCLC): comparison of prognostic factors in 257 patients treated with surgery (S) versus induction chemotherapy plus surgery (IC+S) Source: Eur Respir J 2002; 20: Suppl. 38, 597s Year: 2002
Stage IIIB and stage IV non-small cell lung cancers; responses to treatment and survival durations Source: Eur Respir J 2004; 24: Suppl. 48, 302s Year: 2004
NSCLC stage IV Source: European Multidisciplinary Conference in Thoracic Oncology 2009 Year: 2009
Comparing different initial doses of afatinib used as first-line treatment for patients with stage IV lung adenocarcinoma Source: International Congress 2017 – Clinical research in lung cancer: new valuable results on lung cancer detection, prognostic biomarkers, and tyrosine kinase inhibitors Year: 2017
International guidelines on stage III N2 nonsmall cell lung cancer: surgery or radiotherapy? Source: ERJ Open Res, 6 (1) 00159-2019; 10.1183/23120541.00159-2019 Year: 2020
Docetaxel in combination with carboplatin in the treatment of Stage IIIb and IV non-small cell lung cancer patients. A Phase II study Source: Eur Respir J 2005; 26: Suppl. 49, 77s Year: 2005
Indcution chemotherapy and radiotherapy vs. induction and simultaneous radiochemotherapy in inoperable stage III NSCLC. Update on BROCAT study CTRT 99/97 Source: Eur Respir J 2006; 28: Suppl. 50, 833s Year: 2006
Maintenance treatment with erlotinib after induction chemotherapy for advanced NSCLC Source: Annual Congress 2011 - Recent therapeutic advances with tyrosine-kinase inhibitors in nonsmall-cell lung cancer Year: 2011
A phase III randomised trial assessing the activity of first-line ifosfamide-gemcitabine (IG), a non-platinum chemotherapy (CT), in patients with advanced non-small cell lung cancer (NSCLC) Source: Annual Congress 2011 - Treatment of lung cancer Year: 2011
Is there any survival benefit of surgery after neoadjuvant chemoradiotherapy and persisting pn2/3 in stage III NSCLC? Source: Annual Congress 2009 - Diagnosis and treatment of lung cancer Year: 2009